Level A· Stronger Clinical EvidenceMeta-analysisEurope PMCOpen access

Evaluation of the cardioprotective potential of extracellular vesicles - a systematic review and meta-analysis

Wendt S., Goetzenich A., Goettsch C., Stoppe C., Bleilevens C., Kraemer S.

Meta-analysis on Cardiovascular Disease, published in Sci Rep (2018) — summary generated from the PubMed abstract.

Open my reading list
Level A· Stronger Clinical EvidenceEvidence level of this study

Relatively higher-quality human studies compared with other topics in this database, e.g. multiple RCTs or systematic reviews. This does not mean it is standard or approved care.

  • Level A · Stronger Clinical Evidence
  • Level B · Emerging clinical evidence with positive signals
  • Level C · Early human research exploring benefits
  • Level D · Scientific groundwork from lab and animal studies
  • Emerging · Emerging topic under active research
Read the A–D evidence level guide

This page is generated from the PubMed record. The Thai description is an automated summary of bibliographic fields and the abstract, not a full translation, and is not medical advice.

Study type
Meta-analysis
Journal
Sci Rep (2018)
Reported sample size
—
Source database
Europe PMC
PMID
30356109
PMCID
PMC6200786
DOI
10.1038/s41598-018-33862-5
Citations
31

Abstract (original English)

Cardiovascular diseases are the main cause of death worldwide, demanding new treatments and interventions. Recently, extracellular vesicles (EVs) came in focus as important carriers of protective molecules such as miRNAs and proteins which might contribute to e.g. improved cardiac function after myocardial infarction. EVs can be secreted from almost every cell type in the human body and can be transferred via the bloodstream in almost every compartment. To provide an all-encompassing overview of studies investigating these beneficial properties of EVs we performed a systematic review/meta-analysis of studies investigating the cardioprotective characteristics of EVs. Forty-three studies were investigated and catalogued according to the EV source. We provide an in-depth analysis of the purification method, size of the EVs, the conducted experiments to investigate the beneficial properties of EVs as well as the major effector molecule encapsulated in EVs mediating protection. This study provides evidence that EVs from different cell types and body fluids provide cardioprotection in different in vivo and in vitro studies. A meta-analysis was performed to estimate the underlying effect size. In conclusion, we demonstrated that EVs from different sources might serve as a promising tool for treating cardiovascular diseases in the future.

What this study does not prove

  • • This study does not prove SVF is an approved treatment or a replacement for standard care.

Evidence level

Relatively higher-quality human studies compared with other topics in this database, e.g. multiple RCTs or systematic reviews. This does not mean it is standard or approved care.

How we grade evidence
Cell LineFibroblastsMyocytes, CardiacMesenchymal Stem CellsBody FluidsAnimalsHumansMyocardial InfarctionCardiotonic AgentsIschemic Preconditioning, Myocardial

Browse all related research

Filter the research library by this study's title keywords, author, or publication year.

Related research